Disclosed are a deuterated compound of fomula (I), or a salt thereof, and methods for preparation thereof. The present disclosure may provide a mild, versatile organophotoredox method for the preparation of diverse, enantioenriched α-deuterated α-amino acids. In particular, the present disclosure may address the long-standing challenge of installing sterically demanding side chains into α-amino acids, including late-stage modifications on medicinal agents and natural products.

Provided herein are methods and compounds for targeted autophagy.

Described herein are compounds of the formulae (I)-(III) as well as pharmaceutical compositions comprising such compounds and methods for using such compounds/pharmaceutical compositions for treating Alzheimer's disease.

Described herein are compounds of the formulae (I)-(III) as well as pharmaceutical compositions comprising such compounds and methods for using such compounds/pharmaceutical compositions for treating Alzheimer's disease.

The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as prostaglandin E2 (PGE2) EP4 receptor antagonists, which renders them highly advantageous for use in therapy, particularly in the treatment or prevention of cancer, a neovascular eye disease, inflammatory pain, or an inflammatory disease, such as, e.g., multiple sclerosis, rheumatoid arthritis or endometriosis.

##STR00001##

Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating a condition, disease, or disorder associated with abnormal activation of the SREBP pathway, including metabolic disorders such as obesity, cancer, cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD) wherein the compound is according to Formula (I).

Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating a condition, disease, or disorder associated with abnormal activation of the SREBP pathway, including metabolic disorders such as obesity, cancer, cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD) wherein the compound is according to Formula (I).

Drilling fluid compositions include an emulsifier having a generic structure A, structure B, or a combination thereof. Structure A includes an amide (e.g., amic acid group) and structure B includes a cyclic imide. The emulsifier of the emulsifier system is formed by reacting a fatty oil amine (e.g., oleyl amine), with a cyclic anhydride (e.g., succinic anhydride) in the absence of diluent or in a diluent that does not react with the starting materials. The reaction takes place via application of a stepwise increase in temperature. An emulsifier based on structure A is formed when the reaction temperature is maintained at 50 to 100° C. for 1 to 3 hours. A further increase in reaction temperature (e.g., up to 200° C.) can include water elimination which results predominately in the formation of a molecule represented by structure B.

Drilling fluid compositions include an emulsifier having a generic structure A, structure B, or a combination thereof. Structure A includes an amide (e.g., amic acid group) and structure B includes a cyclic imide. The emulsifier of the emulsifier system is formed by reacting a fatty oil amine (e.g., oleyl amine), with a cyclic anhydride (e.g., succinic anhydride) in the absence of diluent or in a diluent that does not react with the starting materials. The reaction takes place via application of a stepwise increase in temperature. An emulsifier based on structure A is formed when the reaction temperature is maintained at 50 to 100° C. for 1 to 3 hours. A further increase in reaction temperature (e.g., up to 200° C.) can include water elimination which results predominately in the formation of a molecule represented by structure B.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
X-A-Y-L-R  (I)
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.